Fig. 2From: High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysisForest plot of the subgroup analysis assessing the reduction in the depressive symptoms. We reported the mean reduction in BDI scores after 3 months of treatment and in BDI-II and PHQ-9 scores after 6 months of treatmentBack to article page